Acadia Pharma (ACAD) Halted Ahead of FDA PDAC Review of NUPLAZID

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced that NASDAQ has halted trading of the company’s common stock.

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) is meeting today to review NUPLAZID (pimavanserin) for the treatment of patients with psychosis associated with Parkinson’s disease.

The Advisory Committee meeting is scheduled for 8:00 a.m. ET. The briefing materials can be found on the FDA website at http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/ucm475314.htm

You May Also Be Interested In

• Regenxbio shares jump after FDA agrees to reverse drug rejection
• FDA clears expansion of Creative Medical's back pain trial
• Eledon reports Phase 2 kidney transplant drug data at ATC